ischaemic stroke

A laboratory mouse
#ischaemic stroke #Stroke #The University of Manchester

Clot-busting drug could harm stroke treatment response 

A clot-busting drug may stop promising stroke medicine from working properly, research reveals.  Researchers at the University of Manchester found the clot-busting therapy, known as tissue plasminogen activator (tPA), interacts negatively with the anti-inflammatory treatment anakinra, highlighting the need for new stroke therapies alongside existing standard care. Read More

#News

#Clinical trial #Drug discovery #ischaemic stroke #Proteins

How DiaMedica aims to reshape treatments for ischemic diseases

DDW Editor Reece Armstrong speaks to Rick Pauls, CEO of DiaMedica, about the company’s efforts in ischemic diseases and the challenges of drug discovery in this field.   RA: How did DiaMedica decide to explore the therapy area of ischemia?   RP: Ischemic diseases driven by restricted blood flow and endothelial dysfunction, such as preeclampsia (PE), fetal growth restriction (FGR), and… Read More

#Exclusive Content

Laboratory research
#Clinical development #Clinical trial #ischaemic stroke

Lumosa announces positive results from trial of stroke treatment 

Pharmaceutical company Lumosa Therapeutics has announced positive results from its Phase IIb clinical trial of LT3001 in patients with acute ischaemic stroke.  LT3001 met its primary endpoint of safety, with no treatment-related symptomatic intracranial haemorrhage (siCH) observed. The results showed that LT3001 maintained a favourable safety profile… Read More

#News

Blood cells
#ischaemic stroke #Preclinical investigations #Stroke #The University of Manchester

New drug a potential breakthrough for stroke treatment

A new clot-busting drug has been shown in preclinical investigations to be significantly better at treating ischaemic stroke than existing therapies.  The compound, known as caADAMTS13, could be a breakthrough for patients who have brain blood clots with an overabundance of platelets.  The study, funded… Read More

#Editor's Choice #News

Blocked artery
#Aptamers #Basking Biosciences #ischaemic stroke #Phase I trial #RNA

RNA aptamer reopens blocked arteries

Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke.  The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose.   The study results were presented at the… Read More

#News #Trending News

Patient receiving flu vaccine
#Flu vaccine #ischaemic stroke #Stroke

Flu vaccine linked to lower risk of stroke

Getting an annual flu shot may be associated with a lower risk of stroke, Spanish researchers have claimed. The findings, from a study conducted at the University of Alcalá in Madrid, have been published in the journal Neurology. The observational study suggests that those who have a flu shot have… Read More

#News